SPEN

Across TCGA pan-cancer cohorts, SPEN mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SPEN data layer compared with 21 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SPEN mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SPEN expression acts as an unfavorable survival marker, although some lineages such as CCRCC and COAD show a favorable association.

CCRCC, COAD, and HNSC are the cancer types where SPEN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.846	0.504	.003	29	view →
COAD	DFS	Median	II,III,IV	1.000	0.904	.012	24	view →
HNSC	OS	Median	All	0.380	1.000	.008	14	view →
LSCC	OS	Tertile	II,III,IV	0.944	0.664	.014	10	view →
PDAC	DFS	Median	All	0.850	0.737	.025	3	view →
UCEC	DFS	Median	All	1.000	0.939	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SPEN–CCRCC (DFS)

Open the CCRCC breakdown →